CXL-1427

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

CXL-1427 is an experimental drug for the treatment of acute decompensated heart failure. It was created by Cardioxyl Pharmaceuticals, which was acquired by Bristol-Myers Squibb. It is a nitric oxide donor.[1]

CXL-1427 is a prodrug of CXL-1020.[2]

A preliminary study showed efficacy in patients with class III and IV heart failure.[3] A phase II clinical trial was completed in 2016.[4]

References[edit]

  1. ^ Alternative Names: BMS-986231; CXL 1427; HNO Donor. "BMS 986231 - AdisInsight". Adisinsight.springer.com. Retrieved 2017-05-22. 
  2. ^ Alternative Names: CXL-1020. "CXL 1020 - AdisInsight". Adisinsight.springer.com. Retrieved 2017-05-22. 
  3. ^ http://www.mdedge.com/ecardiologynews/article/109035/heart-failure/nitroxl-prodrug-shows-promise-acute-heart-failure
  4. ^ "A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure - Full Text View". ClinicalTrials.gov. Retrieved 2017-05-22.